Abstract
Chronic spontaneous urticaria is defined as recurrent wheals of unknown etiology for more than 6 weeks, with or without angioneurotic edema. The key step in the pathogenesis of chronic spontaneous urticaria is activation and degranulation of mast cells and basophils. Omalizumab, a recombinant humanized IgG monoclonal antibody, can selectively bond the Fc region of free IgE antibodies, and then block IgE-FCeR Ⅰ-mediated activation of mast cells and basophils. Three phase Ⅲ clinical trials have been reported on the efficacy of omalizumab in the treatment of chronic spontaneous urticaria, which confirm the efficacy and safety of omalizumab in the treatment of refractory chronic spontaneous urticaria. Key words: Urticaria; Immunoglobulin epsilon-chains; Omalizumab; Chronic spontaneous urticaria
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
